Why we started
Gelesis was founded with a simple yet powerful mission: to harness the power of nature to address some of the most pressing health challenges of our time affecting millions of people worldwide.
This aspiration sparked years of groundbreaking research into hydrogel technologies.
Today, Gelesis stands at the forefront of biomimicry innovation, developing therapies that work with the body's natural processes to improve health outcomes. Our story is one of persistence, innovation, and an unwavering commitment to making a real difference in people's lives.
Our mission & Core values
Our mission
Improve the lives of millions struggling with obesity, GI and metabolic deaseases through accessible and evidence based solutions derived from our innovative, natured-inspired biomimetic platform
Innovation
We turn research into therapeutic progress through rigorous science and continuous refinement.
Collaboration
We integrate diverse expertise to create cohesive and effective solutions, working together with universities and public and private research institutions
Patient Focus
We measure success by the difference our therapies make in people’s lives.
The Minds Behind the Formula
Our team brings together world-class expertise in biotechnology, biomimicry, clinical research, and pharmaceutical development. Each member is dedicated to pushing the boundaries of what's possible in treating GI-related chronic diseases.
Our technology is engineered to interact with the GI environment in a controlled, local manner. By leveraging biomimetic material properties, we aim to influence GI mechanics and downstream signals associated with appetite regulation and metabolic function. This approach is intended to be evaluated through reproducible endpoints-linking material design to physiological response and clinical outcomes.
Our Vision for the Future
We envision a future where GI-related chronic diseases are no longer a lifelong burden. Through continued innovation in biomimicry and hydrogel technology, we're working to expand our portfolio of therapies to address a broader range of metabolic and digestive health conditions.
Our roadmap includes developing next-generation treatments for Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD/NASH), and other conditions that affect millions worldwide. We're committed to making these therapies accessible, affordable, and backed by rigorous clinical evidence.
Beyond our current pipeline, we're investing in research partnerships with leading academic institutions and exploring new applications of our proprietary platform technology. The future of healthcare lies in solutions that work with the body, not against it, and Gelesis is leading the way.
